This site is intended for healthcare professionals
Responding to unmet needs for metastatic castration-resistant prostate cancer
mCRPC in focus

Transcript: ESMO and NCCN guideline recommendations for mCRPC

Last updated:4th Sep 2024
Published:4th Sep 2024

Professor Axel Merseburger

All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.

So, clinical practice guideline recommendation for metastatic castration-resistant prostate cancer, we have a lot of guidelines, which are highly respected, and good for everyday clinical use; namely, the NCCN or ESMO EAU Guidelines, Which are on a regular basis updated, and guide us to treat men with metastatic castration-resistant prostate cancer.

However, it's not always easy, since we have different patient profiles. Some refuse, for example, chemotherapy. Some asking for novel therapies like theranostics. Some just want to have basic ADT hormone treatment.

So. it's really something you need to discuss with your patient. And, this is what we do and a lot of colleagues also do, to talk, and to educate, and inform the patients on the options we have on metastatic castration-resistant prostate cancer. In summary, the recommendation is to give ADT as backbone treatment lifelong in mCRPC. And then, add on whatever makes sense and whatever is approved in the local healthcare system and reimbursed. And, this taken together, we have a large armamentarium of drugs from hormone treatment, from novel hormone treatments, up to chemotherapy, and recent developments in theranostics, and also immune therapy, which are on the horizon, and in some countries, already approved. So, we have a lot of treatments for this deadly disease, and that have proven to prolong the overall survival of those men with this deadly disease.

View the video

Welcome: